OUR COMMITMENT
Independent, transparent, and flexible.
MedImpact offers plan sponsors certainty that their PBM partner has the freedom to act in their best interest.
OUR COMMITMENT
Clarity.
We empower plan sponsors with clear answers to make the right care and cost decisions and own their future. We are transparent, independent, and flexible.
OUR COMMITMENT
Control.
Our powerful suite of clinical and technology solutions gives plan sponsors command over their strategy, spend, and business results. Because we are delivery-model agnostic, we design and deploy our solutions to meet your needs, not ours.
OUR COMMITMENT
Confidence.
We offer clients peace of mind knowing that their PBM is perfectly aligned with their goals and fully invested in their future. MedImpact is an independent partner, free from ownership interests with health plans and pharmacy chains that create conflicts and misaligned incentives.
HERE FOR YOU
Proven results.
Every client has unique priorities and needs. That's why we are the PBM that offers highly customized benefit designs, formularies, clinical programs and analytics. No one-size-fits-all here. See what we mean:
- How can we be sure our home delivery service is designed with our plan’s best interest in mind?
- READ MORE
- What should we consider when choosing a PBM?
- READ MORE
- Can we make it easier for members to understand their benefits?
- READ MORE
- How can we manage the rising cost of specialty medications?
- READ MORE
- Can we use genetics to achieve better health outcomes?
- READ MORE
- How can I reduce the cost of prescription benefits?
- READ MORE
- How can we help members save money and plans gain access to critical data?
- READ MORE
- Can analytics empower us to make better decisions?
- READ MORE
- What tools are available to help us manage fraud, waste, and abuse?
- READ MORE
- How can we reduce costs and improve outcomes for people on government programs?
- READ MORE
- Can we help doctors and members make better decisions at the point of care?
- READ MORE
WHO WE ARE
We are MedImpact.
For 30 years, MedImpact has been lowering cost, improving care, and delivering better solutions for our clients. Today, we're the largest independent pharmacy benefit solutions company and we are investing millions of dollars in clinical programs, technology, operations, and analytics.
We are excited about the future — that's why we're running toward it and investing to invent it.
MARKET INSIGHTS
MedImpact’s 2019 Annual Trend Report
In 2019, MedImpact provided our clients with the insights, analytics, and solutions to rein in drug spend, while improving outcomes and the consumer experience. We did this by looking beyond the standard pharmacy benefits toolkit and investing in, developing and launching new healthcare solutions – solutions that personalized care, empowered consumers, engaged providers and reduced costs.
RESOURCES
Read on.
Keep up to date on the latest in the industry.
-
- Client news
- FDA approves first and only treatment for common mutation in advanced breast cancer.
- The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.
- READ MORE
-
- Client news
- Can you put a price on life?
- FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.
- READ MORE
-
- Client news
- Investigating top diabetes trends by lines of business.
- Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.
- READ MORE
Ready for clarity from your PBM?
